Evaluation of Antihypertensive Drugs in OSA Patients (ADOSA)

This study has been completed.
Information provided by (Responsible Party):
Universidade Nova de Lisboa
ClinicalTrials.gov Identifier:
First received: February 27, 2013
Last updated: October 31, 2014
Last verified: October 2014
This prospective cohort study aimed to assess the phenotypic characteristics of OSA patients and their pattern of antihypertensive drugs consumption. The investigators also aimed to investigate a hypothetical association between ongoing anti-hypertensive regimen and Blood pressure control rates in these patients. Additionally, the investigators were also interested in trying to understand if the control of OSA may be influenced by the use of different classes of anti-hypertensive drugs.

Obstructive Sleep Apnea

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Antihypertensive Drugs in Patients With Obstructive Sleep Apnea

Resource links provided by NLM:

Further study details as provided by Universidade Nova de Lisboa:

Primary Outcome Measures:
  • Number of participants with uncontrolled BP before CPAP (Continuous Positive Airway Pressure) adaptation. [ Time Frame: patients will be followed up for an expected average time of 2 months ] [ Designated as safety issue: No ]

Enrollment: 369
Study Start Date: April 2010
Study Completion Date: April 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Consecutive patients, male and women, aged above 18 years, that attended a first visit at CHLN Hospital Sleep Unit, located in Lisbon, were enrolled.

Inclusion Criteria:

  • aged above 18 years, that attended a first visit at CHLN Hospital Sleep Unit were enrolled

Exclusion Criteria:

  • severe psychiatric disease or inability to understand the information required for an informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01803815

Universidade Nova de Lisboa - Faculdade de Ciências Médicas
Lisboa, Portugal, 1169-056
Sponsors and Collaborators
Universidade Nova de Lisboa
Principal Investigator: Lucilia N Diogo, PharmD, MSc Universidade Nova de Lisboa - CEDOC
Study Chair: Paula Pinto, PhD, MD CHLN
Study Chair: Cristina Bárbara, PhD, MD CHLN
Study Director: Emilia C Monteiro, PhD, MD Universidade Nova de Lisboa
Study Director: Ana L Papoila, PhD Universidade Nova de Lisboa
  More Information

Additional Information:
No publications provided

Responsible Party: Universidade Nova de Lisboa
ClinicalTrials.gov Identifier: NCT01803815     History of Changes
Other Study ID Numbers: NOVA - CEDOC/FCT 
Study First Received: February 27, 2013
Last Updated: October 31, 2014
Health Authority: Portugal: Ethics Committee for Clinical Research

Keywords provided by Universidade Nova de Lisboa:
obstructive sleep apnea
antihypertensive drugs

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Nervous System Diseases
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders
Sleep Disorders, Intrinsic
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 10, 2016